Dave Ricks

In a lively discussion, Dave Ricks, CEO of Eli Lilly, shares insights from his leadership in developing GLP-1 medicines, including tirzepatide. He dives into the significant impact of these drugs on weight loss and unexpected benefits for addiction and mental health. Ricks addresses the challenges of counterfeit products, pricing dynamics, and the biotech funding landscape. He also explores the future of pharma breakthroughs, highlighting brain diseases as the next frontier, while advocating for better public health policies and patient empowerment through AI.

Dave Ricks, CEO of Eli Lilly, leads a powerhouse in pharma innovation. He dives into the fascinating origins of GLP-1s, tracing back to Gila monster saliva, and their transformative potential beyond weight loss. Ricks discusses the tricky landscape of drug pricing, citing insulin costs and the impact of new models like LillyDirect. He tackles the challenges of clinical trials, regulatory hurdles, and the rise of shadow generics, all while emphasizing the importance of transparency in the healthcare market.

Dave Ricks, CEO of Eli Lilly, shares insights from the J.P. Morgan Healthcare Conference. He discusses the challenges of pricing and accessing GLP-1 obesity medications, despite high demand. Ricks delves into the implications of the Inflation Reduction Act on drug pricing and regulatory hurdles. He emphasizes the importance of business relationships with the incoming Trump administration and aims for Eli Lilly to reach a trillion-dollar valuation in healthcare. The conversation also touches on significant biotech M&A activities and the evolving landscape of drug development.

Dave Ricks, CEO of Eli Lilly, dives into the company's bold $2.5 billion acquisition of Scorpion Therapeutics' breast cancer program, signaling a major commitment to oncology. He discusses the anticipated approval of Lilly's innovative oral weight-loss pill in early 2026 and its potential advantages over current treatments. Ricks also addresses the critical issue of drug pricing, exploring strategies for making new medications accessible while ensuring they deliver value and effective outcomes.

In this discussion, Dave Ricks, CEO of Eli Lilly, shares insights on the company's groundbreaking weight-loss drugs, like Zepbound and terzepatide. He elaborates on their potential in treating addictive behaviors and combating the rising global obesity crisis. Ricks highlights the need for accessible treatments and the complexities of drug manufacturing. He also reflects on his career journey and the transformative impact these medications can have on patients' lives, emphasizing the importance of sustainable health changes.